GSK has entered into a definitive agreement to acquire Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company focused on precision oncology, for approximately $10.6 billion. The deal, announced on June 9, 2026, values Nuvalent shares at $124 each in cash — a 40% premium to the company’s prior closing price — and marks the third major acquisition GSK has executed this year, following its purchase of RAPT Therapeutics for $2.2 billion and an earlier deal with 35Pharma.
The transaction is structured around three non-small cell lung cancer (NSCLC) assets that collectively represent some of the most closely watched late-stage oncology candidates in 2026. Zidesamtinib (NVL-520), a next-generation ROS1 inhibitor, carries an FDA PDUFA target date of 18 September 2026. Neladalkib (NVL-655), a next-generation ALK inhibitor, has a target decision date of 27 November 2026. Both compounds have received FDA Breakthrough Therapy and Orphan Drug Designations, reflecting their potential clinical differentiation in a crowded tyrosine kinase inhibitor space. A third asset, NVL-330, a HER2-targeted inhibitor for HER2-altered NSCLC, is currently in Phase 1 evaluation.
What distinguishes zidesamtinib and neladalkib from earlier-generation inhibitors is their engineered selectivity. ROS1 and ALK fusions are well-validated oncogenic drivers in NSCLC, but resistance to first- and second-generation inhibitors via on-target mutations — particularly at the solvent-front position — has limited long-term clinical benefit. Nuvalent designed both compounds to retain activity against such resistance mutations while minimising off-target kinase engagement, including against TRK. The clinical consequence, demonstrated across Phase 1/2 expansion cohorts, is a tolerability profile that permits sustained dosing even in patients who had progressed on lorlatinib.
For GSK, the acquisition is explicitly a pipeline-replenishment play. The company faces patent cliffs on several revenue-generating assets in the late 2020s, and its oncology portfolio has historically lacked depth in thoracic malignancies. Subject to regulatory approvals, GSK has indicated it expects both lead drugs to launch in 2026 and characterised them as having multi-blockbuster potential. The combined transaction is expected to be accretive to sales and core operating profit in 2027, and to core EPS in 2029 inclusive of synergies and reprioritisation.
The deal is also a barometer for broader industry dynamics. Biotech M&A has reached $106 billion across 201 transactions so far in 2026, putting the sector on pace for its strongest deal year since the pre-pandemic peak. Average deal value has climbed sharply to $527 million, up from $365 million in 2025, reflecting a preference among large-cap acquirers for clinically de-risked, late-stage assets rather than early bets. Nuvalent — with two PDUFA dates before year-end — represented exactly the kind of near-term value crystallisation that has driven this cycle’s deal logic.
The acquisition is subject to customary regulatory approvals and Nuvalent shareholder vote.
